葵花葯業(002737.SZ):簽署成立菌源酶與創新藥物聯合實驗室《合作意向書》
格隆匯12月1日丨葵花葯業(002737.SZ)公佈,公司、北京大學醫學部(以下簡稱"北大醫學部")於近日共同簽署關於成立"北大醫學-葵花藥業集團菌源酶與創新藥物聯合實驗室"(以下簡稱"聯合實驗室")的《合作意向書》,建立合作伙伴關係。合作意向書的主要內容
1、合作方式:成立"北大醫學-葵花葯業集團菌源酶與創新藥物聯合實驗室"。
2、關於資金:
(1)本公司在聯合實驗室協議簽署生效後的 3 年內出資總計不少於人民幣1,000 萬元用於聯合實驗室運營經費及科研經費,並擬於 2025 年 3 月前簽署雙方共建聯合實驗室協議,經費按照聯合實驗室協議約定支付,經費管理由雙方另行書面協商確定。
(2)雙方一致同意立項的項目,經費從本公司已支付的用於聯合實驗室運營及科研經費中支出。
3、聯合實驗室運營:
(1)雙方均有權提出需要解決的前瞻性科學和技術問題。
(2)立項通過後,北大醫學部負責課題研發、聯合攻關、項目資助申請等事務,研發國際一流的先進技術。公司提供必要支持。
4、知識產權:雙方在聯合實驗室中共同研發的技術成果及其相關知識產權為雙方共同所有,具體權益分配另行協商。
5、優先受讓權:公司享有北大醫學部及聯合實驗室研發技術成果優先受讓權。
6、合作意向書有效期至 2025 年 3 月 31 日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.